6505--Diclofenac Sodium (NA) 1% Gel
ID: 36E79725R0012Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/636e4fd97e974a0fbe8c3016e1dd456e/view
Timeline
    Description

    The Department of Veterans Affairs is soliciting proposals for the supply of Diclofenac Sodium (NA) 1% Gel, intended for use in its pharmaceutical programs, including those of the Department of Defense. Contractors are required to provide pricing for a base year along with four one-year option years, and must comply with federal drug regulations, including the Drug Supply Chain Security Act (DSCSA). This procurement is critical for ensuring the availability of quality pharmaceutical products that meet stringent manufacturing standards and regulatory compliance. Interested parties should contact Contract Specialist Ray Roldan at Raymond.Roldan@va.gov for further details regarding the submission process and requirements.

    Point(s) of Contact
    Ray RoldanContract Specialist
    Raymond.Roldan@va.gov
    Files
    Title
    Posted
    36E79725R0012.docx
    The document outlines a Request for Proposals (RFP) issued by the Department of Veterans Affairs (VA) for the supply of Diclofenac NA 1% Gel for the VA and Department of Defense (DoD) pharmaceutical programs. Key points include the requirement for potential contractors to provide pricing for a base year and four one-year option years, with specific instructions for submitting offers and samples. The contractor must adhere to established federal drug regulations and supply chain guidelines, including compliance with the Drug Supply Chain Security Act (DSCSA). The contract will be effective upon signing and will have set delivery and payment terms, with a unique focus on small businesses, including categories like women-owned and service-disabled veteran-owned businesses. The document emphasizes adherence to stringent manufacturing standards and the need for submitted products to have identifiable National Drug Codes (NDCs) or Universal Product Codes (UPCs). It highlights the government's commitment to maintaining compliance while ensuring consistent product availability through its prime vendor network. This RFP illustrates the structured process by which government contracts for pharmaceutical products are awarded, underscoring the criticality of compliance with regulatory standards designed to protect public health and ensure quality supply chains.
    Lifecycle
    Title
    Type
    6505--Diclofenac Sodium (NA) 1% Gel
    Currently viewing
    Solicitation
    6505--Diclofenac Sodium (NA) 1% Gel
    Presolicitation
    Similar Opportunities
    6505--Mycophenolate Mofetil RFP
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Mycophenolate Mofetil capsules and tablets under its Pharmaceutical Prime Vendor Program. The objective of this contract is to establish national pricing for these pharmaceutical products to meet the needs of various government health care facilities, including those under the Department of Defense and Indian Health Service. These medications are critical for patient care within federal health systems, necessitating compliance with FDA standards and the Drug Supply Chain Security Act to ensure safe and reliable distribution. Interested vendors should contact Contract Specialist Amber Zavala at amber.zavala@va.gov for further details, and proposals must include pricing for the base year and four option years as outlined in the solicitation document.
    6505--Phenytoin SA Capsules (VA-25-00022318)
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the supply of Phenytoin Sodium (NA) Extended 100MG Sustained Action Capsules under solicitation number VA-25-00022318. This procurement aims to secure a reliable supply of essential medications for the VA and Department of Defense’s Pharmaceutical Prime Vendor Programs, ensuring consistent access to pharmaceuticals for federal health care facilities. Offerors must comply with federal regulations, including the Drug Supply Chain Security Act, and provide unique 11-digit National Drug Code numbers along with a Letter of Commitment from manufacturers. The deadline for submitting proposals has been extended to February 27, 2025, at 2:30 PM Central Time, and interested parties should contact Contract Specialist Youlanda Duggar at youlanda.duggar@va.gov for further information.
    6505--Fluticasone Propionate 50 MCG/Spray Soln, Nasal, 16GM
    Buyer not available
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Fluticasone Propionate 50 MCG/Spray solution, nasal, 16GM, intended for use by various federal agencies including the Department of Defense, Bureau of Prisons, and Indian Health Service. The objective of this procurement is to secure a reliable and uninterrupted supply of this medication for a contract period of one year, with the possibility of four additional one-year extensions. This medication is crucial for treating nasal conditions, and the estimated annual requirement is approximately 5,784,828 bottles. The solicitation will be available electronically on or around February 11, 2025, with a closing date set for February 25, 2025. Interested vendors should direct inquiries to Michael Olszewski at michael.olszewski@va.gov or call 708-786-4966.
    Valsartan
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    6505--Rituximab and Biosimilars
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Rituximab 10mg/ml and its biosimilars, aimed at establishing a reliable pharmaceutical supply source for government healthcare facilities. Bidders are required to provide unique National Drug Code (NDC) numbers for their products and include a 0.5% Cost Recovery Fee in their pricing, with the contract covering a base year and four optional subsequent years. This procurement is critical for ensuring consistent product availability and pricing based on estimated annual usage, while adhering to FDA regulations and the Drug Supply Chain Security Act (DSCSA) for safety and traceability. Interested suppliers must submit their proposals by March 11, 2025, at 2:30 PM CT, and can contact Contract Specialist Deborah S Fassl at Deborah.Fassl@va.gov for further information.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--Tamsulosin Capsules
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Tamsulosin Hydrochloride capsules as part of its Pharmaceutical Prime Vendor (PPV) Programs. Offerors are required to submit pricing for a base year and four option years, ensuring compliance with FDA standards and providing a unique 11-digit National Drug Code (NDC) for each product. This procurement is vital for maintaining a consistent supply of necessary pharmaceuticals to federal healthcare facilities, adhering to regulatory standards while ensuring availability and pricing stability. Interested parties must submit their offers by February 24, 2025, at 2:30 PM CST, and can contact Contract Specialist Andrew J. Cazares at Andrew.Cazares@va.gov for further information.
    6505--Bevacizumab Injection
    Buyer not available
    The Department of Veterans Affairs (VA) intends to procure Bevacizumab Injections through a Request for Proposal (RFP) designated as 36E79725R0019. This procurement aims to secure an uninterrupted supply of Bevacizumab, a critical pharmaceutical product used in the treatment of various medical conditions, for the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The contract will span one year with four additional one-year option periods, and the estimated annual requirements include various package sizes of Bevacizumab, with a total estimated usage of over 100,000 vials. Interested offerors must submit their proposals by March 4, 2025, at 2:30 PM Central Time, and can direct inquiries to Contract Specialist Matthew Poulin at Matthew.Poulin@va.gov or by phone at 708-786-5186.
    Pantoprazole DR Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Rabeprazole Sodium Delayed Release Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.